SBI Okasan Asset Management Co.Ltd. Buys New Stake in Gilead Sciences, Inc. $GILD

SBI Okasan Asset Management Co.Ltd. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, Holdings Channel reports. The firm bought 13,211 shares of the biopharmaceutical company’s stock, valued at approximately $1,650,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after purchasing an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. grew its position in Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after purchasing an additional 7,168 shares during the last quarter. NewEdge Wealth LLC grew its position in Gilead Sciences by 2.9% in the 3rd quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock worth $75,962,000 after purchasing an additional 17,284 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Gilead Sciences by 16.5% during the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after purchasing an additional 726,101 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Gilead Sciences by 4.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 161,155 shares of the biopharmaceutical company’s stock valued at $17,888,000 after purchasing an additional 6,680 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 1.9%

Shares of NASDAQ GILD opened at $136.22 on Friday. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The company has a market cap of $169.13 billion, a PE ratio of 18.56 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company has a 50-day moving average of $135.43 and a two-hundred day moving average of $134.08.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Analyst Ratings Changes

Several equities analysts recently issued reports on GILD shares. Morgan Stanley cut their price target on shares of Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Cantor Fitzgerald dropped their target price on shares of Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, April 10th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Truist Financial reaffirmed a “buy” rating and issued a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Finally, TD Cowen boosted their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the sale, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This represents a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 53,000 shares of company stock valued at $7,075,670 over the last quarter. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.